A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy
The Oncologist · 2023
DOI: 10.1093/oncolo/oyad036 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2023. Verfasst von Saro Kasparian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, National Institutes of Health.
Abstract (Originalsprache)
Background
Relugolix is the newest form of androgen deprivation therapy (ADT) approved for prostate cancer. However, as an oral drug, several real-world concerns exist, particularly medication compliance, safety with other androgen receptor-targeted agents, and financial burden to patients.
Methods
A single institution retrospective chart review was conducted evaluating all patients who were prescribed relugolix for any prostate cancer indication from January 1, 2021 to January 31, 2022. Demographic data, cardiac risk factors, concomitant therapy usage, and PSA/testosterone levels, were abstracted from the chart review. Adverse effects were obtained by examining progress notes. Compliance was assessed by clinic notes as well as prescription fills by specialty pharmacy records. The reasons patients did not fill or discontinued the medication were noted.
Results
Hundred and one patients were prescribed relugolix, and 91 patients consented to research. Seventy-one (78%) patients filled the prescription to relugolix, with a median follow-up of 5 months. Prescription fill data were available for 45 (63%) patients, with 94% of days covered. The most commonly reported reason not to fill was cost at 50%. Sixty-six (93%) patients reported never missing a dose. PSA levels were available in 71 (100%) patients with 69 (97%) showing stable or improved PSA. Testosterone levels were available in 61 (86%) of patients, which showed 61 (100%) stable or successful castration. Twenty-four (34%) patients used relugolix in combination. No new major safety signals were seen in combination therapy. Nineteen (27%) patients had switched to another form of ADT. Fifteen of these (79%) felt similar or better on relugolix therapy.
Conclusions
Compliance with relugolix seemed acceptable. No major new safety signals were seen, even in combination. Among patients who switched therapy, most tolerated relugolix similarly or better than the previous form of ADT. The cost was a major reason for patients not initiating and for discontinuing therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
- Department of Biostats, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
- Department of Oncology, Providence St Jude Medical Center, Fullerton, CA, USA.
ORCID-Profile: Saro Kasparian, Tanya Dorff
Förderung
- NCI NIH HHS
- National Cancer Institute
- National Institutes of Health
Zitieren
APA
Kasparian, S., Wei, O., Tsai, N. C., Palmer, J., Pal, S., Lyou, Y., & Dorff, T. (2023). A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy. The Oncologist. https://doi.org/10.1093/oncolo/oyad036
Vancouver
Kasparian S, Wei O, Tsai NC, Palmer J, Pal S, Lyou Y, et al. A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy. The Oncologist. 2023. doi:10.1093/oncolo/oyad036
BibTeX
@article{Kasparian2023,
author = {Kasparian, Saro and Wei, Oren and Tsai, Ni-Chun and Palmer, Joycelynne and Pal, Sumanta and Lyou, Yung and Dorff, Tanya},
title = {A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy},
journal = {The Oncologist},
year = {2023},
doi = {10.1093/oncolo/oyad036}
}
EUVIMED